Major and Minor ECG Abnormalities in Asymptomatic Women and Risk of Cardiovascular Events and Mortality

Transcription

1 ORIGINAL CONTRIBUTION Major and Minor ECG in Asymptomatic Women and Risk of Cardiovascular Events and Mortality Pablo Denes, MD Joseph C. Larson, MS Donald M. Lloyd-Jones, MD Ronald J. Prineas, MD Philip Greenland, MD RESTING 12-LEAD ELECTROCARdiogram (ECG) abnormalities are independently associated with incident coronary heart disease (CHD) and cardiovascular disease (CVD) events Many of the prior studies included only men or compared men and women, but the women were not selected for age or the presence or absence of underlying heart disease Data are sparse regarding the prognostic significance of baseline ECG abnormalities in postmenopausal women without clinically manifest heart disease. 14 Furthermore, there is no information on the prognostic significance of incident ECG abnormalities. The Women s Health Initiative (WHI) clinical trials of hormone therapy examined whether in healthy postmenopausal women a combination of estrogen and progestin would reduce CHD and CVD events. 15 The study showed that there was a significant increase in CHD rates among women taking hormone therapy compared with the placebo group. 16 A subsequently published article on the risk of CHD found that clinical characteristics or biomarkers did not significantly modify the treatment-related risk of CHD end points. 17 Context Data are sparse regarding the prevalence, incidence, and independent prognostic value of minor and/or major electrocardiographic (ECG) abnormalities in asymptomatic postmenopausal women. There is no information on the effect, if any, of hormonal treatment on the prognostic value of the ECG. Objective To examine association of minor and major baseline and incident ECG abnormalities with long-term cardiovascular morbidity and mortality. Design, Setting, and Participants Post-hoc analysis of the estrogen plus progestin component of the Women s Health Initiative study, a randomized controlled primary prevention trial of postmenopausal asymptomatic women with intact uterus who received 1 daily tablet containing.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate or a matching placebo. Participants were enrolled from 1993 to 1998, and the estrogen plus progestin trial was stopped on July 7, 22. Main Outcome Measures The vacode criteria were used to define minor, major, and incident ECG abnormalities. Cardiovascular end points included incident coronary heart disease (CHD) and cardiovascular disease (CVD) events. Results Among women with absent (n=9744), minor (n=495), and major (n=91) ECG abnormalities, there were 118, 91, and 37 incident CHD events, respectively. The incident annual CHD event rates per 1 women with absent, minor, or major ECG abnormalities were 21 (95% confidence interval [CI], 18-26), 4 (95% CI, 32-49), and 75 (95% CI, 54-14), respectively. After 3 years of follow-up, 5% of women who had normal ECG at baseline developed new ECG abnormalities with an annual CHD event rate of 85 (95% CI, ) per 1 women. The adjusted hazard ratios for CHD events were 1.55 (95% CI, ) for minor baseline, 3.1 (95% CI, ) for major baseline, and 2.6 (95% CI, ) for incident ECG abnormalities. There were no significant interactions between hormone treatment assignment and ECG abnormalities for risk prediction of cardiovascular end points. For prediction of CHD events, the addition of ECG findings to the Framingham risk score increased from.69 to.74 the area under the receiver operating characteristic curve. Similar findings were found for incident CVD events. Conclusions Among asymptomatic postmenopausal women, clinically relevant baseline and incident ECG abnormalities are independently associated with increased risk of cardiovascular events and mortality, and the information is incremental to the established method of risk stratification. Trial Registration clinicaltrials.gov Identifier: NCT611 JAMA. 27;297: Author Affiliations: Departments of Medicine and Preventive Medicine, rthwestern University, Feinberg School of Medicine, Chicago, Ill (Drs Denes, Lloyd- Jones, and Greenland); Women s Health Initiative Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Wash (Mr Larson); and Department of Epidemiology, Wake Forest University School of Medicine, Winston-Salem, NC (Dr Prineas). Corresponding Author: Pablo Denes, MD, Departments of Medicine and Preventive Medicine, rthwestern University, Feinberg School of Medicine, 251 E Huron, Feinberg 8-34, Chicago, IL JAMA, March 7, 27 Vol 297,. 9 (Reprinted) 27 American Medical Association. All rights reserved.

2 In our study, we examined the association of baseline and incident ECG findings with CHD and CVD outcomes in the placebo and hormonal treatment groups of the WHI estrogen plus progestin trial. 16,17 We hypothesized that baseline minor and major ECG abnormalities and development of new ECG abnormalities during follow-up would be associated with increased incident CHD and CVD outcomes independent of traditional risk factors. We also sought to examine whether hormone use would affect the association between the ECG findings and CVD outcomes. METHODS Study Population, Recruitment, Study Regimens, and Follow-up Detailed eligibility criteria and recruitment methods, randomization, followup, data and safety monitoring, and quality assurance have been published previously Briefly, most participants were recruited by populationbased direct mailing campaigns to women aged 5 to 79 years at initial screening. Postmenopausal women with an intact uterus were eligible for the combined estrogen and progestin trial. Participants were enrolled from 1993 to 1998, and the estrogen plus progestin trial was stopped on July 7, 22. The protocol and consent form were approved by the institutional review boards of all participating institutions, and written informed consent was obtained from all participants. Major exclusion criteria were related to competing risks, safety issues, and adherence For these analyses, we excluded women with history of prior myocardial infarction (MI), angina, congestive heart failure, coronary artery bypass graft surgery, percutaneous transluminal coronary angioplasty or stenting, permanent pacemakers, stroke or transient ischemic attacks, deep venous thrombosis, and pulmonary embolism. The sample analyzed included women with intact uterus who received 1 daily tablet containing.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate (Prempro, Wyeth Ayerst Pharmaceutical, Philadelphia, Pa) or a matching placebo. Follow-up, Data Collection, and Quality Assurance Follow-up contact for clinical events occurred every 6 months, in addition to an annual in-clinic visit. At each semiannual contact, a standardized interview with a self-administered questionnaire was used to collect information on symptoms and safety concerns. Standard 12-lead ECGs were taken at baseline and at follow-up years 3 and 6. The data and safety monitoring board stopped the trial early at an average follow-up of 5.2 years, because health risks exceeded health benefits in the active treatment group compared with placebo. 16 Race/ethnicity was determined by selfreport questionnaire. 15 Outcome Ascertainment Coronary heart disease was defined as acute MI necessitating overnight hospitalization, silent MI identified on serial ECGs, or death due to CHD. Detailed definitions for the diagnosis of acute MI and death due to CHD were previously published and are based on standardized criteria Cardiovascular disease end points included CHD (CHD death and nonfatal MI), coronary artery bypass graft surgery/percutaneous transluminal coronary angioplasty, and stroke (fatal and nonfatal). 16,17 ECG Analysis Standard 12-lead ECGs were recorded at baseline and the annual visit at year 3 in the resting supine position using strictly standardized procedures in all clinical centers. 14 All ECGs received at the central ECG laboratory (EPICARE Center, University of Alberta, Alberta, Edmonton, and later in Wake Forest University, Winston-Salem, NC) were inspected visually to detect technical errors, missing leads, and inadequate quality, and such records (n=255) were rejected from ECG data files. ECG data were stored electronically and transmitted daily to the Electrocardiographic Reading Center for analysis by using the vacode criteria measurement and classification system. 18 ECG abnormalities were divided into minor and major abnormalities on the basis of the vacode system, which is a modification of the criteria used in the Pooling Project. 9 The Pooling Project was a US national cooperative study of 5 longitudinal investigations on the incidence of heart disease that was the first to categorize individual ECG findings into minor and major groupings, and used the Minnesota code for coding individual ECG abnormalities. We used a hierarchical categorization. Women with only minor ECG abnormalities were classified as having minor abnormalities; women with both minor and major abnormalities were classified as having major abnormalities. Women without minor or major ECG abnormalities were classified as having marginal/absent abnormalities and their ECG was considered normal. Criteria for minor prevalent ECG abnormalities were any of the following: (1) first- and second-degree atrioventricular block (vacode 2.1 and 2.2.1); (2) borderline prolonged ventricular excitation (vacode and 3.4.2); (3) prolonged ventricular repolarization (vacode and 4.1.2); (4) isolated minor Q and ST-T abnormalities (vacode 5.7 and 5.8); (5) left ventricular hypertrophy without ST-T abnormalities (vacode 6.1.); (6) left atrial enlargement (vacode 7.1); (7) frequent atrial or ventricular premature beats (Minnesota code 8.1); and (8) fascicular blocks (vacode 1.1 and 1.2). Criteria for major prevalent ECG abnormalities were any of the following: (1) atrial fibrillation or atrial flutter (vacode 1.5); (2) high-degree atrioventricular dissociation (vacode and 2.3.2); (3) left bundle-branch block (vacode 3.1. and 3.1.1); (4) right bundle-branch block (vacode 3.2.); (5) indeterminate conduction delay (vacode 3.3. and 3.3.1); (6) Q- wave MI (vacode 5.1, 5.2, 5.3, and 5.4); (7) isolated ischemic abnormalities (vacode 5.5 and 5.6); (8) left ventricular hypertrophy with ST-T abnormalities (vacode 6.1.1); and (9) other vacode 1.4, 1.7, 1.8, 1.9, and 2.4, which refer to miscellaneous ar- 27 American Medical Association. All rights reserved. (Reprinted) JAMA, March 7, 27 Vol 297,

3 rhythmias (eg, supraventricular tachycardia, ventricular preexcitation, ventricular tachycardia) with less than 5 participants being included in the analysis and not listed individually. Criteria for incident ECG abnormalities were any of the following: (1) new atrial fibrillation or flutter (vacode I 1.5); (2) new prolonged ventricular excitation (vacode I 3.1, I 3.2, I 3.3, and I 3.4); (3) new prolonged ventricular repolarization (vacode I 4.1.); (4) new left ventricular hypertrophy (vacode I and I 6.1.2); (5) new Q-wave MI (vacode I 5.1, I 5.2, I 5.3, and I 5.4); and (6) new ischemic ST-T evolution (vacode I 5.5, I 5.6.1, I 5.6.2, and I 5.7). Statistical Analysis Associations between continuous baseline variables and ECG abnormality status were assessed by using 2-sample t tests and presented with means (SDs). Associations with categorical baseline variables were assessed with 2 tests and presented with sample sizes and percentages. To evaluate outcome occurrence, results are presented with the number of events, percentage of total participants with the event, the rate per 1 women per year, and a 95% confidence interval (CI) for the rate. Kaplan-Meier survival curves were estimated and compared between ECG groups by using the Table 1. Baseline Clinical Characteristics of the Study Group (N = )* Characteristics rmal (n = 9744) Electrocardiographic Findings Minor Prevalent (n = 495) Major Prevalent (n = 91) P Value Age at screening, y Mean (SD) 62.2 (7.) 63.9 (7.) 66. (7.1) (14.8) 413 (1.1) 51 (5.6) (23.5) 89 (19.8) 136 (15.) (44.9) 1889 (46.1) 411 (45.2) (16.8) 984 (24.) 312 (34.3) BMI, mean (SD) 27.9 (5.6) 29.4 (6.2) 29. (6.1).1 Blood pressure, mean (SD), mm Hg Systolic (16.8) 13.7 (17.6) (19.3).1 Diastolic 75.2 (8.9) 76.8 (9.2) 77. (9.6).1 Race/ethnicity White 8279 (85.) 3398 (83.) 752 (82.6) Black 534 (5.5) 327 (8.) 86 (9.5) Hispanic 545 (5.6) 218 (5.3) 34 (3.7) American Indian 3 (.3) 15 (.4) 2 (.2).1 Asian/Pacific Islander 221 (2.3) 77 (1.9) 28 (3.1) Other/unknown 135 (1.4) 6 (1.5) 8 (.9) Smoking Never 4742 (49.13) 219 (52.) 428 (47.61) Past 3863 (4.) 1547 (38.1) 373 (41.5) Current 146 (1.8) 4 (9.9) 98 (1.9).2 Parental history of premature MI 928 (12.6) 45 (13.3) 79 (11.5).36 History of treated diabetes mellitus 317 (3.3) 21 (5.1) 44 (4.8).1 Treatment for hypercholesterolemia 89 (1.2) 474 (12.6) 114 (13.5).1 Statin use 51 (5.2) 252 (6.2) 63 (6.9).2 Hypertension (blood pressure or self-report of medications used) 59 (54.8) 2722 (68.7) 668 (75.3).1 Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); MI, myocardial infarction. *Data are presented as number (percentage) unless otherwise specified. Includes nonresponders as well as those participants who selected this category. Never smoker indicates participants have never smoked at least 1 cigarettes in their lifetime; past smoker indicates participants did not smoke at the time of the study but may have smoked at least 1 cigarettes in their lifetime; and current smoker indicates participants who currently smoke and have smoked at least 1 cigarettes in their lifetime. log-rank test. A crude relative risk was estimated from the event rates. Adjusted hazard ratios (HRs) for the association between outcome occurrences and ECG abnormalities were modeled with Cox proportional hazards regression models, and stratified by randomization status in the Dietary Modification trial of the WHI. 15 The proportional hazards assumption was checked by modeling each outcome (CHD and CVD) by a time by baseline ECG status interaction term in a proportional hazards model along with the baseline ECG main effects term. This was not significant for CHD (interaction P=.29) and borderline for CVD (interaction P=.1), indicating that the proportional hazards assumption was satisfied. Cox proportional hazards regression models were adjusted for estrogen plus progestin treatment assignment, age, ethnicity, history of treated diabetes mellitus, hypertension, current smoking, self-reported pills for cholesterol and statin use, and body mass index (calculated as weight in kilograms divided by height in meters squared). The resulting HRs and 95% CIs are presented. In addition to the main analyses, subgroups were examined to investigate an interaction effect between baseline ECG status and the majority of the above risk factors, with an additional factor of parental history of premature MI. To evaluate this interaction, the P value of an interaction term from a Cox proportional hazards regression model with main effects of the subgroup of interest and baseline ECG status as well as their interaction were calculated. All Cox proportional hazards regression analyses were complete case and excluded a small percentage of participants ( 1%) with missing data. Additional models were constructed to look at the effect on outcome association by adding ECG data to existing CHD risk criteria; in this case, the Framingham risk score for 1- year CHD risk. To evaluate this, the likelihood ratio test was used for both the incident CHD and CVD outcomes. First, a Cox proportional haz- 98 JAMA, March 7, 27 Vol 297,. 9 (Reprinted) 27 American Medical Association. All rights reserved.

4 ards regression model was fit with the outcome of interest as a function of the Framingham CHD risk score. 19 A second model was then fit with the Framingham score as well as the baseline ECG variable (normal, minor and major abnormalities). The difference between the 2 log likelihoods of the 2 models was then tested against a 2 statistic with 2 df, with a significance level of P.5 being used to determine significant improvement from the Framingham-only model to the Framingham plus ECG model. We also ran logistic models to compare the differences between the Framingham-only and Framingham plus ECG models. C statistics and receiver operating characteristic curves were completed for each of these models. Because the Framingham score calculation already involves covariates that were previously used as adjustments, the only adjustment used in these comparison analyses was randomization status in the WHI Dietary Modification trial. Calculation of the Framingham risk score also requires measured cholesterol information. Because of this, both the survival and logistic analyses involving Framingham risk score were limited to participants in the WHI blood subsample (n=1264). All analyses were performed by using SAS version 9.1 (SAS Institute Inc, Cary, NC). All tests were 2-sided and P.5 was considered statistically significant. RESULTS Baseline Characteristics We identified participants of the WHI estrogen plus progestin trial who at baseline had no history of prior MI, angina, coronary interventions, coronary artery bypass graft surgery, stroke, or transient ischemic attacks. A total of 7593 women were randomized to estrogen plus progestin group and 7156 were assigned to placebo. Baseline characteristics of the study group are shown in TABLE 1. At the baseline examination, the ECG was normal in 9744 women (66.%), 495 women (27.8%) had minor abnormalities, and 91 women (6.2%) had major abnormalities. Women in the group with ECG abnormalities were older, had a higher body mass index, and were more likely to have a history of treated diabetes, hypercholesterolemia, and hypertension. ECG Findings and Outcomes The mean follow-up was 5.6 years, with a maximum of 8.6 years. A total of 246 women had CHD events and 595 had CVD events. TABLE 2 shows the number of women and the adjusted HRs for each component of the CHD and CVD outcomes, and total mortality. The strongest association of both minor and major ECG abnormalities was with CHD death. Baseline Minor ECG The crude rates and the multivariableadjusted HRs associated with the presence of minor ECG abnormalities were significantly higher compared with those women with absent ECG abnormalities (TABLE 3). The Kaplan-Meier estimates, shown in FIGURE 1, show a significant difference in CHD and CVD outcomes (log-rank P.1) between absent and minor ECG abnormality Table 2. Hazard Ratios for Cardiovascular Outcomes by ECG Abnormality Status at Baseline*. of Women With rmal ECG (n = 9744). of Women Minor Prevalent (n = 495) HR (95% CI). of Women Major Prevalent (n = 91) HR (95% CI) CVD ( ) ( ) CHD ( ) ( ) nfatal MI Including silent MI ( ) ( ) Excluding silent MI ( ) ( ) CHD death ( ) ( ) CABG/PTCA ( ) ( ) Stroke ( ) ( ) Total mortality ( ) ( ) Abbreviations: CABG, coronary artery bypass graft; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; ECG, electrocardiogram; HR, hazard ratio; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty. *CHD includes acute MI necessitating overnight hospitalization, silent MI identified on serial ECGs, or death due to CHD. CVD end points included CHD (CHD death and nonfatal MI), CABG/PTCA, and stroke (fatal and nonfatal). Adjusted HRs and nominal 95% CIs are shown and stratified according to age and randomly assigned dietmodification group. Referent group is women with no baseline ECG abnormalities. Table 3. Baseline ECG and Outcomes for the Study Group* Incident CHD Incident CVD Absent or marginal abnormalities (n = 9744). of outcomes (% of total) 118 (1.2) 34 (3.1) Annual events/1 women (95% CI) 21 (18-26) 55 (49-62) Minor abnormalities (n = 495). of outcomes (% of total) 91 (2.2) 28 (5.1) Annual events/1 women (95% CI) 4 (32-49) 91 (79-14) Crude RR Adjusted HR (95% CI) 1.55 ( ) 1.39 ( ) Major abnormalities (n = 91). of outcomes (% of total) 37 (4.1) 83 (9.1) Annual events/1 women (95% CI) 75 (54-14) 168 (136-29) Crude RR Adjusted HR (95% CI) 3.1 ( ) 2.34 ( ) Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; ECG, electrocardiogram; HR, hazard ratio; RR, relative risk. *CHD includes acute myocardial infarction (MI) necessitating overnight hospitalization, silent MI identified on serial ECGs, or death due to CHD. CVD end points included CHD (CHD death and nonfatal MI), coronary artery bypass graft surgery/percutaneous transluminal coronary angioplasty, and stroke (fatal and nonfatal). Relative risks and adjusted HRs and nominal 95% CIs are shown and stratified according to age and randomly assigned diet-modification group. Referent group is women with no baseline ECG abnormalities. 27 American Medical Association. All rights reserved. (Reprinted) JAMA, March 7, 27 Vol 297,

5 Figure 1. Kaplan-Meier Estimates of Coronary Heart Disease and Cardiovascular Disease Cumulative Hazard Over Time in Years for rmal, Minor, and Major Baseline ECG Coronary Heart Disease Cardiovascular Disease Cumulative Hazard Major Baseline ECG Minor Baseline ECG rmal Log-Rank P<.1 Cumulative Hazard Log-Rank P< at Risk Major Baseline ECG Minor Baseline ECG rmal Time, y Time, y ECG indicates electrocardiogram. Table 4. Baseline ECG and Outcomes for the Estrogen Plus Progestin and Placebo Groups* Incident CHD Incident CVD Estrogen Plus Progestin Group Absent or marginal abnormalities (n = 518). of outcomes (% of total) 6 (1.2) 158 (3.2) Annual events/1 women (95% CI) 21 (16-27) 55 (47-64) Minor abnormalities (n = 299). of outcomes (% of total) 62 (3.) 129 (6.2) Annual events/1 women (95% CI) 53 (41-68) 11 (92-13) Crude RR Adjusted HR (95% CI) 1.83 ( ) 1.61 ( ) Major abnormalities (n = 476). of outcomes (% of total) 19 (4.) 44 (9.2) Annual events/1 women (95% CI) 74 (47-115) 17 ( ) Crude RR Adjusted HR (95% CI) 2.97 ( ) 2.48 ( ) Placebo Group Absent or marginal abnormalities (n = 4726). of outcomes (% of total) 58 (1.2) 146 (3.1) Annual events/1 women (95% CI) 22 (17-28) 55 (47-65) Minor abnormalities (n = 1996). of outcomes (% of total) 29 (1.5) 79 (4.) Annual events/1 women (95% CI) 26 (18-38) 71 (57-89) Crude RR Adjusted HR (95% CI) 1.2 ( ) 1.16 ( ) Major abnormalities (n = 434). of outcomes (% of total) 18 (4.1) 39 (9.) Annual events/1 women (95% CI) 77 (48-122) 166 ( ) Crude RR Adjusted HR (95% CI) 3.7 ( ) 2.23 ( ) Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; ECG, electrocardiogram; HR, hazard ratio; RR, relative risk. *CHD includes acute myocardial infarction (MI) necessitating overnight hospitalization, silent MI identified on serial ECGs, or death due to CHD. CVD end points included CHD (CHD death and nonfatal MI), coronary artery bypass graft surgery/percutaneous transluminal coronary angioplasty, and stroke (fatal and nonfatal). Relative risks and adjusted HRs and nominal 95% CIs are shown and stratified according to age and randomly assigned diet-modification group. Referent group for both the estrogen plus progestin and placebo groups is women with no baseline ECG abnormalities. groups. There was an excess of 36 (95% CI, 23-5) CVD events per 1 women per year compared with those women with absent ECG abnormalities. When we examined the placebo and estrogen plus progestin groups separately (TABLE 4), the adjusted HRs of incident CHD and CVD were consistently higher among the hormonetreated group compared with the placebo group, although the HRs in the placebo group did not reach significance due to the small number of outcomes. Baseline Major ECG As shown in Table 3, the crude rates of incident and the multivariableadjusted HRs associated with the presence of major ECG abnormalities were significantly higher compared with those women with absent ECG abnormalities. The Kaplan-Meier estimates, shown in Figure 1, show a significant difference in CHD and CVD outcomes (log-rank P.1) between the absent and major ECG abnormality groups. There was an excess of 113 (95% CI, 79-15) CVD events per 1 women per year compared with those women with absent ECG abnormalities. When we examined separately the placebo and estrogen plus progestin groups for the adjusted HRs of inci- 982 JAMA, March 7, 27 Vol 297,. 9 (Reprinted) 27 American Medical Association. All rights reserved.

6 dent CHD and CVD events, we did not find a consistent difference between the hormone-treated and placebo groups (Table 4). Incident ECG A total of (86%) of women came for their third-year visit (follow-up ECG). There were 7717 women with normal baseline ECG who had no CHD, congestive heart failure, angina, or CVD events before the 3-year follow-up and whose ECG remained normal (referent group). Incident ECG abnormalities developed in 45 women (5%). The annual event rate per 1 women for incident CHD was 85 (95% CI, ). The multivariableadjusted HRs associated with the presence of incident ECG abnormalities were 2.6 (95% CI, ) for CHD and 2.86 (95% CI, ) for CVD events. Subgroup Analysis To determine whether the presence of ECG abnormalities (minor and major) were more predictive of cardiovascular outcome in selected subgroups of women, we examined several demographic and clinical characteristics of the estrogen plus progestin trial participants (FIGURE 2). Despite differences noted in HRs associated with minor ECG abnormalities, there were no significant interactions between ECG abnormalities and hormone treatment in the risk for CVD events (Table 4 and Figure 2). Likewise, we observed no other significant interactions between ECG abnormalities across different strata of women. The interaction between ECG abnormalities and ethnicity was of borderline significance (Figure 2). Usefulness of ECG as Predictor of Outcome When added to the Cox proportional hazards regression models, which looked at CHD and CVD as a function of Framingham CHD risk score, baseline ECG abnormality status significantly improved each model and was evaluated Figure 2. Risk of Cardiovascular Disease in Various Subgroups. of Cardiovascular Disease Events (Annualized %) Estrogen Plus Progestin Trial Treatment Assignment Placebo Estrogen Plus Progestin Age at Screening, y Race/Ethnicity White nwhite History of Treated Diabetes Hypertension Smoking Pills for Cholesterol Statin Use Parental History of Premature MI CHD Risk Factors rmal ECG Prevalent 146 (.55) 118 (.88) 158 (.55) 173 (1.2) 14 (.16) 16 (.57) 42 (.32) 33 (.61) 153 (.63) 127 (1.) 95 (1.8) 115 (1.67) 252 (.53) 248 (1.7) 52 (.65) 43 (.92) 264 (.49) 253 (.96) 4 (2.32) 37 (2.71) 7 (.3) 55 (.69) 215 (.75) 231 (1.24) 255 (.52) 244 (.98) 42 (.71) 45 (1.64) 213 (.49) 24 (.94) 42 (.91) 58 (1.88) 279 (.53) 263 (1.1) 25 (.94) 28 (1.68) 171 (.47) 168 (.93) 43 (.85) 39 (1.52) 47 (.25) 44 (.62) 127 (.73) 131 (1.17) 15 (2.) 21 (3.58) P Value for Interaction Hazard Ratio (95% CI) 1 ECG indicates electrocardiogram; CHD, coronary heart disease; MI, myocardial infarction; CI, confidence interval. Cardiovascular disease end points included CHD (CHD death and nonfatal MI), coronary artery bypass graft surgery/percutaneous transluminal coronary angioplasty, and stroke (fatal and nonfatal). Prevalent abnormalities include major and minor ECG abnormalities. The CHD risk factors are current smoker, parental history of premature MI (mother aged 65 years or father aged 55 years), hypertension, pills for cholesterol, and treated diabetes. 27 American Medical Association. All rights reserved. (Reprinted) JAMA, March 7, 27 Vol 297,

7 with the likelihood ratio test (P=.4 for CHD and P=.2 for CVD). This improvement was also observed by looking at the receiver operating characteristic curves and C statistics computed from logistic regression (FIGURE 3). The area under the receiver operating characteristic curve increased from.69 (95% CI, ) to.74 (95% CI,.66-.9) for CHD and.68 (95% CI, ) to.7 (95% CI, ) for CVD, with the addition of baseline ECG abnormalities to a model with the Framingham risk score. COMMENT In a large cohort of postmenopausal, asymptomatic women who were without a history of prior CVD and participating in the estrogen plus progestin group of the WHI trial, we found that minor and major baseline ECG abnormalities were associated with significantly increased risks for CHD and CVD events, independent of established risk factors and hormone treatment. Several previous studies that evaluated nonspecific repolarization abnormalities of the ECG in women found significant associations between CHD outcomes and ECG abnormalities. 2,3,7,12,13 The 2 prior studies that examined the prognostic significance of minor and major ECG abnormalities in women showed similar significant association between CHD outcomes and ECG abnormalities independent of clinical variables. 8,11 A recent publication on the ECG abnormalities of women participating in the WHIstudyshowedthatrepolarizationabnormalities, such as wide QRS/T angle, QT prolongation, high QRS nondipolar voltage, and reduced heart rate variability, predict CHD events and mortality. 14 However,theseECGabnormalitiesarenot easily characterized or diagnosed by clinicians without computer assistance. We used the ECG classification of minor and major abnormalities because they are simple, easily defined and interpreted by clinicians, and widely applicable in the clinical setting. Our study is in agreement withthepreviousstudyfindings. 2,3,7,8,11-13 In addition, we provide new information regardingincidentecgabnormalitiesand the associated increased risk of coronary morbidity and mortality. We also found that increasing severity of the ECG findings, when defined as the presence of minor and major abnormalities, correlate with increasing risk for CVD events and mortality. The Kaplan-Meier estimates of cumulativehazardforcvdeventsshowed a significant difference, with an early onsetoftheseparationofthecurves, forboth ECG abnormalities (Figure 2). We present new information showing that in a subgroup of women with complete data on the Framingham risk score, the ECG provides incremental information for risk stratification of CHD events beyond the standard risk factors (Figure 3). The risks for CVD events associated with ECG abnormalities were similar across multiple subgroups, although we did observe evidence for an interaction between ECG abnormalities and ethnicity that was of borderline statistical significance, suggesting that white women with an abnormal baseline ECG have a higher risk for CVD risk than nonwhite women did. Hormonal Therapy and ECG Findings There is clinical and experimental evidence that there are sex-related differences in cardiac repolarization and possibly arrhythmias. 2 In our study, the use of estrogen and progestin did not affect the overall CVD risk assessment by the ECG significantly. Study Limitations Limitations to our study should be considered. The effect of ethnicity on our findings could not be adequately evaluated because study participants (84%) were white. Confirmation of our Figure 3. Receiver Operating Characteristic Curves for Modeling Incident CHD and CVD by Framingham Risk Score With and Without Additional ECG Adjustment Incident CHD Incident CVD Specificity Specificity Sensitivity Sensitivity Framingham Risk Score With ECG Adjustment Without ECG Adjustment Specificity Specificity CHD indicates coronary heart disease; CVD, cardiovascular disease; ECG, electrocardiogram. For incident CHD, the C statistic with ECG adjustment is.74 and without ECG adjustment is.69; and for incident CVD, the C statistic with ECG adjustment is.7 and without ECG adjustment is JAMA, March 7, 27 Vol 297,. 9 (Reprinted) 27 American Medical Association. All rights reserved.

8 findings in other studies of women with larger minority participation would be useful. Second, not all patients with baseline ECG presented for a repeat ECG at year 3 and many of those who did only had a short period of follow-up because the trial was terminated prematurely. Third, there was an underascertainment of increased low-density lipoprotein and other biochemical markers that were not included in the analysis or were not measured but may be associated with ECG abnormalities. Finally, data for the Framingham risk score determination was available only in a limited number of participants and our study findings need to be confirmed in a larger population with longer follow-up. Clinical Implications Given the low cost, wide availability, and ease of interpretation, the ECG may be a useful tool for assisting in the prediction of future cardiovascular events in asymptomatic postmenopausal women. The presence of ECG abnormalities should promptphysicianstoconsiderfurtherrisk stratification, more intensive therapeutic interventions, or both on modifiable risk factors for primary prevention of cardiovascular events. Author Contributions: Mr Larson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Denes, Lloyd-Jones, Prineas, Greenland. Acquisition of data: Denes, Larson, Prineas, Greenland. Analysis and interpretation of data: Denes, Larson, Lloyd-Jones, Greenland. Drafting of the manuscript: Denes, Larson, Lloyd-Jones. Critical revision of the manuscript for important intellectual content: Denes, Larson, Lloyd-Jones, Prineas, Greenland. Statistical analysis: Denes, Larson, Lloyd-Jones. Obtained funding: Greenland. Administrative, technical, or material support: Prineas, Greenland. Study supervision: Lloyd-Jones, Greenland. Financial Disclosures: ne reported. A Short List of Women s Health Initiative Investigators: Program Office: National Heart, Lung, and Blood Institute, Bethesda, Md: Barbara Alving, Jacques Rossouw, Shari Ludlam, Linda Pottern, Joan McGowan, Leslie Ford, and Nancy Geller. Clinical Coordinating Center: Fred Hutchinson Cancer Research Center, Seattle, Wash: Ross Prentice, Garnet Anderson, Andrea LaCroix, Charles L. Kooperberg, Ruth E. Patterson, and Anne McTiernan; Wake Forest University School of Medicine, Winston- Salem, NC: Sally Shumaker; Medical Research Labs, Highland Heights, Ky: Evan Stein; and University of California, San Francisco: Steven Cummings. Clinical Centers: Albert Einstein College of Medicine, Bronx, NY: Sylvia Wassertheil-Smoller; Baylor College of Medicine, Houston, Tex: Jennifer Hays; Brigham and Women s Hospital, Harvard Medical School, Boston, Mass: JoAnn Manson; Brown University, Providence, RI: Annlouise R. Assaf; Emory University, Atlanta, Ga: Lawrence Phillips; Fred Hutchinson Cancer Research Center, Seattle, Wash: Shirley Beresford; George Washington University Medical Center, Washington, DC: Judith Hsia; Harbor-University of California Los Angeles Research and Education Institute, Torrance, Calif: Rowan Chlebowski; Kaiser Permanente Center for Health Research, Portland, Ore: Evelyn Whitlock; Kaiser Permanente Division of Research, Oakland, Calif: Bette Caan; Medical College of Wisconsin, Milwaukee: Jane Morley Kotchen; MedStar Research Institute/Howard University, Washington, DC: Barbara V. Howard; rthwestern University, Evanston, Ill: Linda Van Horn; Rush Medical Center, Chicago, Ill: Henry Black; Stanford Prevention Research Center, Stanford, Calif: Marcia L. Stefanick; State University of New York at Stony Brook, Stony Brook: Dorothy Lane; The Ohio State University, Columbus: Rebecca Jackson; University of Alabama at Birmingham, Birmingham: Cora E. Lewis; University of Arizona, Tucson/Phoenix: Tamsen Bassford; University at Buffalo, Buffalo, NY: Jean Wactawski-Wende; University of California at Davis, Sacramento: John Robbins; University of California at Irvine, Irvine: F. Allan Hubbell; University of California at Los Angeles, Los Angeles: Howard Judd; University of California at San Diego, LaJolla/Chula Vista: Robert D. Langer; University of Cincinnati, Cincinnati, Ohio: Margery Gass; University of Florida, Gainesville/Jacksonville: Marian Limacher; University of Hawaii, Honolulu: David Curb; University of Iowa, Iowa City/Davenport: Robert Wallace; University of Massachusetts/Fallon Clinic, Worcester: Judith Ockene; University of Medicine and Dentistry of New Jersey, Newark: rman Lasser; University of Miami, Miami, Fla: Mary Jo O Sullivan; University of Minnesota, Minneapolis: Karen Margolis; University of Nevada, Reno: Robert Brunner; University of rth Carolina, Chapel Hill: Gerardo Heiss; University of Pittsburgh, Pittsburgh, Pa: Lewis Kuller; University of Tennessee, Memphis: Karen C. Johnson; University of Texas Health Science Center, San Antonio: Robert Brzyski; University of Wisconsin, Madison: Gloria E. Sarto; Wake Forest University School of Medicine, Winston-Salem, NC: Denise Bonds; Wayne State University School of Medicine/Hutzel Hospital, Detroit, Mich: Susan Hendrix. Funding/Support: The Women s Health Initiative program was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health, US Department of Health and Human Services. Role of the Sponsors: The funding organization had representation on the Steering Committee, which governed the design and conduct of the study, the interpretation of the data, and the preparation and approval of the manuscript. A National Heart, Lung, and Blood Institute Program officer reviewed the manuscript prior to publication. REFERENCES 1. Ashley EA, Raxwal VK, Froelicher VF. The prevalence and prognostic significance of electrocardiographic abnormalities. Curr Probl Cardiol. 2;25: Liao Y, Liu K, Dyer A, et al. Sex differential in the relationship of electrocardiographic ST-T abnormalities to risk of coronary death: 11.5 years follow-up findings of the Chicago Heart Association Detection Project in Industry. Circulation. 1987;75: Kannel WB, Anderson K, McGee DL, Degatano LS, Stampfer MJ. nspecific electrocardiographic abnormality as a predictor of coronary heart disease: the Framingham Study. Am Heart J. 1987;113: Sigurdsson E, Sigfusson N, Sigvaldason H, Thorgeirsson G. Silent ST-T changes in an epidemiologic cohort study: a marker of hypertension or coronary heart disease, or both: the Reykjavik Study. JAmColl Cardiol. 1996;27: Cullen K, Stenhouse NS, Wearne KL, Cumpston GN. Electrocardiograms and 13-year cardiovascular mortality in Busselton Study. Br Heart J. 1982;47: Knutsen R, Knutsen SF, Curb JD, Reed DM, Kautz JA, Yano K. The predictive value of resting electrocardiograms for 12-year incidence of coronary heart disease in the Honolulu Heart Program. J Clin Epidemiol. 1988;41: De Bacquer D, De Backer G, Kornitzer M, Myny K, Doyen Z, Blackburn H. Prognostic value of ischemic electrocardiographic findings for cardiovascular mortality in men and women. J Am Coll Cardiol. 1998; 32: De Bacquer D, De Backer G, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart. 1998;8: The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis. 1978;31: Cedres BL, Liu K, Stamler J, et al. Independent contribution of electrocardiographic abnormalities to risk of death from coronary heart disease, cardiovascular diseases and all causes: findings of three Chicago epidemiologic studies. Circulation. 1982;65: Liao YL, Liu KA, Dyer A, et al. Major and minor electrocardiographic abnormalities and risk of death from coronary heart disease, cardiovascular diseases and all causes in men and women. J Am Coll Cardiol. 1988;12: Daviglus ML, Liao Y, Greenland P, et al. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. JAMA. 1999;281: Greenland P, Xie X, Liu K, et al. Impact of minor electrocardiographic ST segment and/or T-wave abnormalities on cardiovascular mortality during longterm follow-up. Am J Cardiol. 23;91: Rautaharju PM, Kooperberg C, Larson JC, La- Croix A. Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women: the Women s Health Initiative. Circulation. 26;113: Design of the Women s Health Initiative clinical trial and observational study: the Women s Health Initiative Study Group. Control Clin Trials. 1998;19: Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA. 22;288: Manson JE, Hsia J, Johnson KC, et al; Women s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 23;349: Rautaharju PM, Park LP, Chaitman BR, Rautaharju F, Zhang ZM. The vacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. J Electrocardiol. 1998; 31: Wilson PW, D Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: Cheng J. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanism in different animal species and human. Fundam Clin Pharmacol. 26;2: American Medical Association. All rights reserved. (Reprinted) JAMA, March 7, 27 Vol 297,